Register
Haematologica 2019 Aug 14
Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.   

Related Questions

How do you manage recurrent portal vein thromboses in a patient with JAK2+ PV on therapeutic anticoagulation and appropriate cytoreduction?
Recurrent thromboses despite therapeutic enoxaparin. Other hypercoagulable work-up negative. 
New comment by at Johns Hopkins University ( March 15, 2022)
My thought about the liver as a site of thrombosis in PV is that nitric oxide scavenging by the increased number of red cells is the cause similar to increased nitric oxide sc...
In someone with an asymptomatic JAK2 V617 mutated and BCR/ABL negative MPN with a steadily rising WBC, when do you decide to start cytoreductive therapy and which agent(s) do you recommend?
No evidence of palpable splenomegaly, normal hematocrit and platelet count
New answer by at Johns Hopkins University (June 28, 2022)
First, let's abandon the phase "BCR/ABL-negative MPN". This is an oxymoron because BCR/ABL can be expressed in a JAK2 driver mutation-positive MPN. In fact, both BCR/ABL and J...
When you send for molecular studies for polycythemia vera, what are the mutations that predict increased cardiovascular risk?
How do you use this information in clinical practice?
New comment by Medical Oncologist at Aspirus UW Cancer Center ( May 11, 2023)
Great review. Thank you 
Copyright © 2024 theMednet
All Rights Reserved.